[go: up one dir, main page]

DK1951254T3 - (4- (6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL) ¨-5-CHLORTHIOPHEN-2-YL-SULPHONYLURAES AND FORMS AND PROCEDURES RELATED TO IT - Google Patents

(4- (6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL) ¨-5-CHLORTHIOPHEN-2-YL-SULPHONYLURAES AND FORMS AND PROCEDURES RELATED TO IT

Info

Publication number
DK1951254T3
DK1951254T3 DK06827506.4T DK06827506T DK1951254T3 DK 1951254 T3 DK1951254 T3 DK 1951254T3 DK 06827506 T DK06827506 T DK 06827506T DK 1951254 T3 DK1951254 T3 DK 1951254T3
Authority
DK
Denmark
Prior art keywords
sulphonyluraes
chlorthiophen
quinazolin
dioxo
dihydro
Prior art date
Application number
DK06827506.4T
Other languages
Danish (da)
Inventor
Wolin Huang
Mukund Mehrotra
Xiaoming Zhang
Hilary Cannon
Craig M Grant
Robert M Scarborough
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Application granted granted Critical
Publication of DK1951254T3 publication Critical patent/DK1951254T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK06827506.4T 2005-11-03 2006-11-03 (4- (6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL) ¨-5-CHLORTHIOPHEN-2-YL-SULPHONYLURAES AND FORMS AND PROCEDURES RELATED TO IT DK1951254T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73365005P 2005-11-03 2005-11-03
PCT/US2006/043093 WO2007056219A2 (en) 2005-11-03 2006-11-03 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Publications (1)

Publication Number Publication Date
DK1951254T3 true DK1951254T3 (en) 2012-05-07

Family

ID=38023842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06827506.4T DK1951254T3 (en) 2005-11-03 2006-11-03 (4- (6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL) ¨-5-CHLORTHIOPHEN-2-YL-SULPHONYLURAES AND FORMS AND PROCEDURES RELATED TO IT

Country Status (20)

Country Link
US (3) US8058284B2 (en)
EP (2) EP2428514A1 (en)
JP (1) JP5509406B2 (en)
KR (1) KR101423483B1 (en)
CN (1) CN101300013B (en)
AR (1) AR056762A1 (en)
AT (1) ATE540034T1 (en)
AU (1) AU2006311795B2 (en)
BR (1) BRPI0618210A2 (en)
CA (1) CA2627719C (en)
CY (1) CY1112826T1 (en)
DK (1) DK1951254T3 (en)
EA (1) EA017402B1 (en)
ES (1) ES2380814T3 (en)
IL (1) IL191193A (en)
NZ (2) NZ567747A (en)
PT (1) PT1951254E (en)
TW (2) TW200728260A (en)
WO (2) WO2007056219A2 (en)
ZA (1) ZA200804241B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512273A (en) 2004-06-18 2008-02-19 Millennium Pharm Inc xa factor inhibitors
KR101423483B1 (en) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
EA020045B1 (en) * 2007-05-02 2014-08-29 Портола Фармасьютиклз, Инк. Combination therapy with a compound acting as a platelet adp receptor inhibitor
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
KR20100029746A (en) 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
MX2009013431A (en) * 2007-06-18 2010-01-15 Sanofi Aventis Pyrrole derivatives as p2y12 antagonists.
CN101654441B (en) * 2008-08-19 2012-10-03 信谊药厂 Anticoagulant compound, composition and application thereof
CA2743639A1 (en) * 2008-11-14 2010-05-20 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
JP5597202B2 (en) 2009-08-28 2014-10-01 第一三共株式会社 3- (biaryloxy) propionic acid derivatives
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
JP5796872B2 (en) 2009-12-17 2015-10-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Crystalline salt of factor Xa inhibitor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
WO2014042176A1 (en) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 Method for producing fused-heterocyclic derivative, and production intermediate thereof
RU2556198C1 (en) * 2014-04-10 2015-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Method for prevention of postpericardiotomy syndrome in patients with ischemic heart disease after coronary bypass surgery
HK1255034A1 (en) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
TW202432544A (en) 2022-09-07 2024-08-16 美商亞文納營運公司 Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE845042C (en) 1950-07-14 1952-07-28 Basf Ag Process for the preparation of sulfonyl urethanes, ureas or carboxylic acid amides
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (en) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "SULFONYL UREAS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en) 1993-02-19 2001-07-31 G. D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
WO1994021602A1 (en) 1993-03-15 1994-09-29 G.D. Searle & Co. Urea derivatives useful as platelet aggregation inhibitors
TW448161B (en) 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JPH0881442A (en) 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd Cyclic amide derivative
US6413724B1 (en) * 1996-10-28 2002-07-02 Versicor, Inc. Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
JPH10195323A (en) 1997-01-09 1998-07-28 Nippon Paper Ind Co Ltd New sulfonylguanidine compound and thermal recording material prepared by using the same
SE9702774D0 (en) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (en) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド Platelet ADP receptor inhibitor
JP2000204081A (en) 1998-02-05 2000-07-25 Takeda Chem Ind Ltd Sulfonamide derivative, its production and use
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4574100B2 (en) 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ， インコーポレイテッド Platelet ADP receptor inhibitor
ATE502928T1 (en) * 2000-11-01 2011-04-15 Millennium Pharm Inc NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
AU2004278030C1 (en) * 2003-10-03 2010-12-02 Portola Pharmaceuticals, Inc. 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
KR101423483B1 (en) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
KR20100029746A (en) * 2007-05-02 2010-03-17 포톨라 파마슈티컬스, 인코포레이티드 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto

Also Published As

Publication number Publication date
EP2428514A1 (en) 2012-03-14
NZ596025A (en) 2013-08-30
CA2627719A1 (en) 2007-05-18
EP1951254A4 (en) 2009-05-27
EA017402B1 (en) 2012-12-28
AU2006311795B2 (en) 2013-01-17
EP1951254A2 (en) 2008-08-06
EP1951254B1 (en) 2012-01-04
KR101423483B1 (en) 2014-07-28
NZ567747A (en) 2011-11-25
JP2009515836A (en) 2009-04-16
US20070208045A1 (en) 2007-09-06
JP5509406B2 (en) 2014-06-04
US8058284B2 (en) 2011-11-15
IL191193A (en) 2014-04-30
AU2006311795A1 (en) 2007-05-18
EA200801245A1 (en) 2008-10-30
CY1112826T1 (en) 2016-02-10
TWI397529B (en) 2013-06-01
WO2007056219A3 (en) 2007-12-27
TW200728260A (en) 2007-08-01
ES2380814T3 (en) 2012-05-18
US20120088736A1 (en) 2012-04-12
CA2627719C (en) 2016-07-12
HK1121051A1 (en) 2009-04-17
WO2007056167A2 (en) 2007-05-18
BRPI0618210A2 (en) 2011-08-23
WO2007056167A3 (en) 2007-10-04
AR056762A1 (en) 2007-10-24
CN101300013B (en) 2012-11-28
US20070123547A1 (en) 2007-05-31
PT1951254E (en) 2012-04-12
ZA200804241B (en) 2009-09-30
WO2007056219A2 (en) 2007-05-18
KR20080071167A (en) 2008-08-01
TW200804356A (en) 2008-01-16
CN101300013A (en) 2008-11-05
ATE540034T1 (en) 2012-01-15

Similar Documents

Publication Publication Date Title
DK1951254T3 (en) (4- (6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL) ¨-5-CHLORTHIOPHEN-2-YL-SULPHONYLURAES AND FORMS AND PROCEDURES RELATED TO IT
DK2234985T3 (en) 4- (4-cyano-2-thioaryl) dihydropyrimidinones and their use
NO345062B1 (en) 4-Phenyl-6- (2,2,2-trifluoro-1-phenylethoxy) pyrimidine-based compounds and their use
DK2200985T3 (en) 1,3-Disubstituted 4- (aryl-X-phenyl) -1H-pyridin-2-ones
EP1868650A4 (en) KOVALENTE DIABODIES AND ITS USE
DK1954140T3 (en) GLYCEROLLEVULINETKETALS AND THEIR USE
DE602006011787D1 (en) KER
DE502006004431D1 (en) rivet
DK2526858T3 (en) Assessment of sleep quality and sleep-breathing disorders based on cardiac-lung coupling
ATE500232T1 (en) CRYSTALLINE FORM OF 2-CHLORINE-5-Ä3,6-DIHYDRO-3- METHYL-2,6-DIOXO-4-(TRIFLUORMETHYL)-1-(2H)- PYRIMIDINYLÜ-4-FLUORINE-N-ÄÄÄMETHYL-(1- METHYLETHYL)AMINOUSULFONYLUBENZAMIDE
EP1782832A4 (en) REMEDY AGAINST DIABETES
ATE531712T1 (en) SUBSTITUTED ARYLOXAZOLES AND THEIR USE
DE502005005635D1 (en) Double coupling
DK2019090T3 (en) Substituted beta-phenyl-alpha-hydroxypropanoic acid, method of synthesis and use thereof
DK3309233T4 (en) COMPOSITIONS INCLUDING HFC-1234YF AND HFC-152A
DE502005007106D1 (en) SUBSTITUTED PHENYLAMINOTHIAZOLE AND ITS USE
DK1937276T3 (en) IMPROVED TESTOSTERONGEL AND PROCEDURE TO USE THEREOF
NO346419B1 (en) Ethanol-precipitated Phaseolus vulgaris extracts, their use and formulations
NO20050638D0 (en) Reversible quick coupler
DE602006007300D1 (en) Double coupling
EP1853274A4 (en) 2-METHYLENE-19-NOR- (20S-24S) -1ALPHA, 25-D HYDROXYVITAMINE-D2
NO344962B1 (en) Amorphous cesiumaluminum fluorocomplex, its preparation and use
ATE520664T1 (en) TYROSINE KINASE INHIBITORS
DE602006000612D1 (en) Reversible orthosis
DE502006007801D1 (en) ANTENNA ARRANGEMENT AND USE